Shareholder Investigation of Nobilis Health

Nobilis Health Corp. (HLTH) Accused of Overstating Revenue

According to the complaint against the company’s officers and directors for alleged violations of the Securities Exchange Act of 1934 between May 8, 2018 and November 15, 2018, Nobilis Health Corp. (HLTH) failed to disclose that its accounts receivable and revenue were overstated and need re-evaluation and adjustment. On August 2, 2018, the truth began to emerge when Nobilis Health reported that a new accounting standard regarding account receivable had impacted revenue. On this news, Nobilis Health’s share price fell $0.20, or 17.39%, to $0.95. On November 9, 2018, Nobilis filed a Form 12b-25, stating that it was unable to timely file its quarterly report. On this news, Nobilis Health’s share price fell $0.18, more than 25%, to $0.52. Then, on November 12, 2018, Nobilis Health announced it was not in compliance with the NYSE’s listing requirements. The company’s stock fell to just $0.48, and continues to trade significantly below its pre-class high.

Nobilis Health Corp. (HLTH) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.

Send us a message for more information.

Skip to content